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Concentrations of N-terminal pro brain natriuretic peptide
(NT-proBNP) increase in patients with heart failure and other
cardiovascular (CV) diseases and are strong prognostic
markers. In patients with end-stage renal disease (ESRD) in
hemodialysis (HD), levels of NT-proBNP are almost always
raised. In ESRD patients undergoing HD, we aimed at
(i) identifying the factors that affect levels of NT-proBNP,
(ii) determining the effect of HD on NT-proBNP, and
(iii) determining the prognostic impact of NT-proBNP. A total
of 109 patients underwent physical examination,
electrocardiogram, and echocardiography. Serum NT-proBNP
was measured before and after HD (Elecsys 2010). NT-proBNP
levels were markedly elevated (pre-HD 4079 pg/ml, post-HD
2759 pg/ml, Po0.001). There was a strong inverse correlation
between NT-proBNP and left ventricular ejection fraction
(LVEF) (P¼ 0.043), 24-h urine production (P¼ 0.006), and Kt/V
(efficacy of dialysis) (P¼ 0.016) and a positive correlation with
left ventricular hypertrophy (LVH) (P¼ 0.014). Patients with
higher concentrations, both pre- and post-HD had an
increased mortality rate compared to those with lower
concentrations (P¼ 0.007, P¼ 0.002). We found age
(P¼ 0.009) and NT-proBNP (pre-HD P¼ 0.007, post-HD
P¼ 0.001) predictive of death. Our findings demonstrate that
CV disease in terms of LVH and reduced LVEF in addition
to 24-h urine production and Kt/V determine NT-proBNP
levels. Post-HD levels of NT-proBNP were lower than pre-HD
levels; both predictive of mortality.
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Natriuretic peptides (NPs) for the diagnosis of heart failure
have been a diagnostic breakthrough in cardiology, where
determination of the concentration in serum can help
identify patients with left ventricular systolic dysfunction.1,2
The main physiological function of NP is homeostasis and
protection of among others the cardiovascular (CV) system
from the effects of volume overload. They play an important
role in regulating blood pressure (BP) and body fluid volume
by their natriuretic and diuretic actions, arterial dilatation,
and inhibition of the renin–angiotensin system.3 NPs are
synthesized in the cardiac ventricles by cleavage of a
precursor protein, pro brain natriuretic peptide (proBNP),
into a 32-amino-acid active hormone B-type natriuretic
peptide (BNP; MW 3.5 kDa) and a biologically inactive 76-
amino-acid peptide N-terminal pro-BNP (NT-proBNP; MW
8.5 kDa), and released into the circulation on an equimolar
basis upon ventricular myocyte stretch.4 Concentrations of
NP increase in patients with congestive heart failure (CHF)
and other CV diseases owing to pressure and volume
overload, whereas levels below cutoff are a strong negative
predictor for CHF.1,5,6 In patients with end-stage renal
disease (ESRD) treated with hemodialysis (HD), plasma
levels of NP are almost always markedly raised for reasons
largely unknown.7 As a consequence of diminutive residual
renal function, volume overload facilitating left ventricular
strain could be responsible for the elevated concentrations,
but it is also widely recognized that cardiac function is a
major confounder for the interpretation of plasma concen-
trations of NP in chronic renal failure. Furthermore, as the
kidneys are generally thought to be partly responsible for the
elimination of NP, decreased clearance by the clearance
receptors in renal tissue could contribute to the elevated
concentrations. Earlier research has hypothesized that the
measurement of NP could be of use in monitoring excess
fluid volume and dry weight in dialysis patients,8,9 but this
remains to be proven and the significance of plasma NP and
their clinical role in HD patients is still unclear. Measuring
NT-proBNP may have analytical advantages over BNP
because of greater stability due to a longer half-life and the
present study aimed at (i) identifying the factors that affect
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the concentrations of circulating NT-proBNP, (ii) deter-
mining the effect of dialysis on NT-proBNP levels, and
(iii) investigating the prognostic impact of elevated concen-
trations of NT-proBNP in patients undergoing regular HD.
RESULTS
Table 1 shows the characteristics of the included 109 patients
on chronic HD. No patients were lost to follow-up. The
median duration of HD treatment before entry into the study
was 20 months (range 1–216 months). At initiation of HD
treatment, 87 patients (79.8%) were classified as hyperten-
sive, but only 22 patients (20.2%) were hypertensive on 24-h
ambulatory BP monitoring at entry into the study owing to
antihypertensive treatment. Of the total population, 18.3%
were on no antihypertensive treatment, 23.9% were treated
with one antihypertensive drug (50% of these with diuretics),
23.9% were treated with two antihypertensives, 26.6% were
treated with three antihypertensives, and 7.3% were treated
with four or more drugs. On treatment average, systolic BP
was 143.6722.1 mm Hg and average diastolic BP
78.5713.5 mm Hg. LVMI was 46.8713.6 g/m2.7 in male
subjects and 46.3718.5 g/m2.7 in female subjects with LVH
detected in 40 patients (36.7%). LVEF was 50.7713.0%. The
mean value of Kt/V per week was 4.570.9.
Serum NT-proBNP levels were markedly elevated in these
patients (predialysis 4079 pg/ml (median; interquartile range
1893–15076) and post-dialysis 2759 pg/ml (1078–11070),
Po0.001; Figure 1) compared to population-based normal
values.10 Compared to the cutoff level of 125 pg/ml when
screening symptomatic patients for left ventricular systolic
dysfunction, all patients had predialysis levels above the
cutoff with only one patient below this level post-dialysis.
The mean reduction in concentration during dialysis was
38.8713.6%. There was no correlation between the amount
of fluid drawn during HD and the difference in pre- and
post-dialysis levels of NT-proBNP or the decrease in
concentration in percent. The mean reduction in pre- to
post-cartridge levels of NT-proBNP was 7.0%.
Patients with CHF had a significantly higher median
predialysis concentration of NT-proBNP than patients not
having been diagnosed with CHF (15 323 (3576–35 473)
pg/ml, n¼ 26 vs 3355 (1603–9654) pg/ml, n¼ 83, P¼ 0.001).
This is also seen in patients with chronic obstructive
pulmonary disease (24 523 (3744–51 495) pg/ml, n¼ 15 vs
3536 (1789–10 792) pg/ml, n¼ 94, P¼ 0.007). This remains
significant when excluding chronic obstructive pulmonary
disease patients also diagnosed with CHF (P¼ 0.042). We
found no difference in predialysis levels of NT-proBNP
between male and female patients, previously transplanted vs
non-transplanted patients, or in patients with or without
documented coronary artery disease, atrial fibrillation, or
diabetes mellitus. Also, no significant correlation was found
between predialysis levels of NT-proBNP and duration of
renal disease or period of time undergoing HD treatment.
Multivariate linear regression analysis demonstrated a
strong inverse correlation between predialysis ln NT-proBNP
and LVEF (P¼ 0.043), 24-h urine production (P¼ 0.006)
and Kt/V (P¼ 0.016) and a positive correlation with LVH
(P¼ 0.014) (Table 2). The result was almost identical when
investigating post-dialysis ln NT-proBNP. Tertiles of variables
Table 1 | Baseline characteristics of 109 study participants
Age (years)a 61.8 (19–88)
Sex (m/f), N 82/27
Duration of renal disease (years)b 3.0 (1–42)
Duration of dialysis treatment (months)b 20.0 (1–216)
History of IHD (%) 26.6
History of CHF (%) 23.9
History of diabetes (%) 34.9
Atrial fibrillation (%) 11.0
History of hypertension (%) 79.8
Hypertension on treatment (%) 20.2
Former transplantation (%) 9.2
Systolic BP (mm Hg)c 143.6722.1
Diastolic BP (mm Hg)c 78.5713.5
LVEF (%)b 50.7713.3
LVH (%) 36.7
LVMI (M/F, g/m2.7)c 46.8713.6/46.3718.5
BP, blood pressure; CHF, chronic heart failure; F, female; IHD, ischemic heart disease;
LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMI, left
ventricular mass index; M, male.
aExpressed as mean, range in parenthesis.
bExpressed as median, range in parenthesis.
cExpressed as mean with s.d.
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Figure 1 | Pre- and post-dialysis concentrations of NT-proBNP
(4079 vs 2759 pg/ml; median values, Po0.001).
Table 2 | Factors affecting the concentration of circulating
NT-proBNP in patients undergoing chronic HD (predialysis)
Independent variable P-value b
Age (years) NS
Gender NS
IHD NS
LVH 0.014 0.241
LVEF 0.043 0.202
24-h urine production 0.006 0.273
Volume overload NS
Kt/V 0.016 0.246
IHD, ischemic heart disease; HD, hemodialysis; LVEF, left ventricular ejection fraction;
LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro brain natriuretic
peptide.
Volume overload: predialysis weight above estimated dry weight; Kt/V: K=dialyzer
clearance, t=time, V=volume of water a patient’s body contains.
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significantly affecting NT-proBNP levels are shown in
Figure 2. There was no correlation between ln NT-proBNP
and age or gender. As a surrogate marker for volume
overload, we used the increase in body weight in relation to
clinically estimated dry weight, but found no correlation
between this and levels of NT-proBNP (correlation coeffi-
cient 0.090, P¼ 0.65). Quartiles of volume overload in
relation to levels of NT-proBNP are shown in Figure 3.
During the mean follow-up of approximately 2 years
(7127258 days), 34 patients died (nine from cardiac events).
Both pre- and post-dialysis levels of NT-proBNP were
significantly higher in patients who died during follow-up
than in surviving patients (predialysis 6393 (3272–31 381) vs
3352 (1626–10 425) pg/ml, n¼ 34, P¼ 0.002; post-dialysis
6130 (2633–23 084) vs 1837 (948–4707) pg/ml, n¼ 75,
Po0.001). Kaplan–Meier estimates revealed an increased
mortality rate in patients with concentrations above median
values compared to those with lower concentrations, both
pre- and post-dialysis (P¼ 0.007 vs P¼ 0.002) (Figure 4)
with a hazard ratio (HR) of 2.665 (1.262–5.586; predialysis
values). Excluding patients who have undergone renal
transplantation during follow-up did not change the result.
Univariate Cox regression analysis (Table 3) found the
following factors to be predictive of death in this population:
ln predialysis NT-proBNP (P¼ 0.002), ln post-dialysis NT-
proBNP (Po0.001), high sensitivity C-reactive protein
(P¼ 0.002), age (P¼ 0.003), reduced ejection fraction (EF)
(P¼ 0.011), and diabetes mellitus (P¼ 0.034). Other tradi-
tional markers in serum predicting mortality in patients in
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Figure 2 | Serum concentrations of NT-proBNP graphically shown for variables (tertiles) significantly affecting levels in a multivariate
linear regression analysis (LVEF in modified tertiles). Significance between groups is indicated by * and **Po0.05.
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Figure 3 | Serum concentrations of NT-proBNP graphically shown
for volume overload (quartiles).
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HD such as cholesterol, phosphate, and homocysteine were
not significant in our population just as left ventricular end
diastolic diameter, LVMI, and body mass index did not
predict mortality. Apart from NT-proBNP, only age revealed
significance in a multivariate Cox regression analysis;
predialysis: age (P¼ 0.009; HR 1.04 (1.01–1.06)), and
ln NT-proBNP (P¼ 0.007; HR 1.42 (1.10–1.82)), post-
dialysis: age (P¼ 0.009; HR 1.04 (1.01–1.07)) and ln NT-
proBNP (P¼ 0.001; HR 1.52 (1.18–1.96)). Receiver operator
characteristics curves for NT-proBNP as predictor of
subsequent death demonstrated the following areas under
the curve: predialysis 0.718 and post-dialysis 0.729 (Figure 5).
Serum albumin is still the most powerful predictor of death
(HR 5.959 (2.519–14.096; median) and is not included in
these calculations.
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Figure 4 | Kaplan–Meier survival curves according to
concentrations of NT-proBNP above and below median values
(pre- and post-dialysis).
Table 3 | Uni- and multivariate Cox regression analysis for mortality
Univariate Multivariate predialysis Multivariate post-dialysis
Independent variable P-value b P-value HR P-value HR
Age (years) 0.003 0.038 0.009 1.04 (1.01–1.06) 0.009 1.04 (1.01–1.07)
Gender NS — — — —
IHD NS — — — —
DM 0.031 0.742 NS NS
LVMI NS — — — —
LVEF 0.009 0.030 NS NS
LVEDD NS — — — —
ln NT-proBNP (pre-HD) 0.002 0.403 0.007 1.42 (1.10–1.82) — —
ln gNT-proBNP (post-HD) o0.001 0.502 — — 0.001 1.52 (1.18–1.96)
BMI NS — — — — —
hsCRP 0.002 0.190 NS NS
S-cholesterol NS — — — — —
S-phosphate NS — — — — —
S-homocysteine NS — — — — —
BMI, body mass index; DM, diabetes mellitus; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; IHD, ischemic heart disease; LVEDD, left ventricular end diastolic
diameter; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NS, nonsignificant; NT-proBNP, N-terminal pro brain natriuretic peptide.
1 - Specificity
Concentration
(mg/ml) Sensitivity Specificity Hazard ratio
2515 0.875 0.431 3.473 (1.338 – 9.015)
3722 0.750 0.597 2.993 (1.362 – 6.317)
4079 0.718 0.611 2.665 (1.262 – 5.586)
7557 0.500 0.750 2.179 (1.099 – 4.323)
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Figure 5 | Receiver operator characteristics curve for pre- and
post-dialysis concentrations of NT-proBNP with sensitivity,
specificity, and hazard ratio at different cutoff levels of
predialysis concentrations of NT-proBNP. Areas under the receiver
operator characteristics curve for pre- and post-dialysis values are
0.718 and 0.729, respectively. *Median value.
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The number of CV events was too small to reveal any
statistical differences regarding NT-proBNP.
DISCUSSION
This study shows that serum concentrations of NT-proBNP
are greatly elevated in patients with ESRD undergoing HD
and hence they cannot be used as a marker of heart failure in
this population. HD induces a significant decrease of NT-
proBNP levels, which is consistent with one previous report,
whereas another study has shown increasing values.11,12 Wahl
et al.,12 reported that pre- and post-dialysis levels of NT-
proBNP are dependent on the type of membrane used during
HD. High-flux membranes have a higher ultrafiltration rate
than low-flux membranes. They tend to have larger pores,
which means that the clearance of NT-proBNP with a
molecular weight of 8.5 kDa is higher than when using low-
flux membranes, where the post-dialysis concentration
increased. In our substudy, the mean reduction in pre- to
post-cartridge levels was 7.0%, which can be attributed to
adhesion to or elimination over the cartridge. Supportive of
the eliminating effect of HD on concentrations is also the fact
that our levels were dependent of the effectiveness of dialysis
as assessed by Kt/V. However, reduced synthesis may also
contribute considering the abrupt fall in intra-vascular
volume occurring during dialysis in combination with the
half-life of NT-proBNP of 120 min.4 There was no correlation
between ln NT-proBNP and volume overload being an
indicator of left ventricular strain, suggesting that other
factors than fluid retention predominate in regulating
concentrations.
Most studies regarding NP and dialysis have been
investigating BNP and have demonstrated a positive correla-
tion between levels of BNP and, for example, LVMI, LV
diameters, arterial pressure and pulmonary artery pressure,
and the inverse correlation with LVEF.13–17 This is in
agreement with existing evidence on NP in the general
population,2,18–22 but conclusions of the same consistence of
other NP in HD patients cannot be drawn. In our study,
despite the massive elevation of NT-proBNP concentrations,
they nevertheless correlated with LVH and reduced LVEF,
when performing a multivariate linear regression analysis.
Levels of NT-proBNP in the general population are also age-
and sex related as established, for example, by Raymond
et al.,23 but these differences cannot be detected in this
population of patients in HD. These results suggest that the
massively elevated concentrations in part are based on the
same parameters as in patients without renal insufficiency,
but with different impact: age and gender seem to be of
minor importance as opposed to factors affecting left
ventricular dimensions and function.
Another debatable issue in explaining the elevated
concentrations is the elimination of NT-proBNP. NPs are
cleared from the organism by NP receptors in the renal
vascular endothelium, but also by proteolysis primarily by
neutral endopeptidase located in the glomeruli.24,25 There is
no evidence regarding affinity of the different clearance
mechanisms for the various NP, but the clearance mechanism
for NT-proBNP vs BNP is thought to be primarily renal
because of a stronger correlation with estimated glomerular
filtration rate (0.60 vs 0.20).1 Also, NT-proBNP has been
detected in urine in both healthy subjects and patients with
heart failure,26,27 but experience in this area is limited. Our
results sustain this hypothesis given the correlation between
increased 24-h urine production and lower concentrations of
NT-proBNP levels. If a substantial part of the elimination of
NT-proBNP were assumed to take place in the kidneys, an
increase in the circulating concentrations would be anti-
cipated if not compensated for by other ways of elimination.
The clearance of peptides in the kidney is load dependent28
and conditioned on extraction ratio and renal blood flow
(clearance¼ extraction ratio renal blood flow). If one or
more of these parameters are affected, as seen in end-stage
renal failure, it can cause a substantial rise in measured
concentration owing to recirculating substances, but the
importance of reduced elimination by the kidneys and its
contribution to the elevated concentrations is still unknown.
Patients with CHF or chronic obstructive pulmonary
disease had significantly elevated concentrations compared to
HD patients not having been diagnosed with any of these
disorders, which can be ascribed to the additional strain of
the ventricles. We did not find an increased mortality rate
among patients with diabetes mellitus compared to patients
without diagnosed diabetes mellitus, just as we did not find
any significant difference in the concentration of NT-proBNP
in the two groups as earlier described by Naganuma et al.16
As previously established by several studies, the level of
NT-proBNP is a strong prognostic marker in both the general
population29 and in various disease states, for example, acute
and CHF,30,31 coronary heart disease,32,33 and hypertension.34
The information on the prognostic role in patients with
ESRD on HD is sparse with only one study demonstrating
elevated levels of NT-proBNP predictive of all-cause death.35
In our study, concentrations of NT-proBNP revealed
increasing mortality with concomitant increasing concentra-
tions, which was shown for both pre- and post-dialysis
values. This complements the findings of Apple et al.,35 who
demonstrated that NT-proBNP was a marker for mortality
prediction in ESRD if tertile analysis was used.
Multivariate Cox regression analysis revealed only age and
NT-proBNP to be predictive of all-cause death. Therefore,
although large variation and poor sensitivity and specificity,
substantially increased levels of NT-proBNP in HD patients
could be interpreted as an individual risk marker with the
aim of identifying high-risk patients. Even though the
synthesis and by that the level of NT-proBNP may decrease
further initially after dialysis because of minor myocyte
stretch, either pre- or post-dialysis NT-proBNP may function
as a baseline marker for each individual patient. A putative
therapeutic aim could be to identify patients who would
benefit from a more aggressive clinical evaluation and
therapeutic intervention in order to diminish concentrations
as much as possible and to presumably reduce mortality risk.
552 Kidney International (2007) 71, 548–554
o r i g i n a l a r t i c l e LH Madsen et al.: NT-proBNP predicts mortality in ESRD
We defined CV death as sudden death or death caused by
arrhythmias, acute myocardial infarction or CHF. Of the 34
patients who died during follow-up, 25 patients died from
non-CV causes with elevated levels of NT-proBNP being
predictive of total mortality. In our study, 26 patients suffered
from CHF with a mortality rate of 50% during follow-up;
only three patients classified as CV deaths. The most likely
explanation for the predictive value of mortality of NT-
proBNP despite the low incidence of CV death may be based
on misclassification of cause of death owing to other
concomitant disease or the clinical impact of CHF on the
general condition of the patients resulting in deterioration
with subsequent death.
We did not find any correlation between volume overload
and NT-proBNP, which is consistent with a study performed
by Clerico et al.,11 who was unable to detect any correlation
between NT-proBNP and acute changes in preload during
dialysis. This might lessen the possible use of NT-proBNP as
a more accurate marker for estimated dry weight for
sufficient HD, but further research within this area is needed.
Limitations to this study are that the sample size and
number of adverse events are relatively small and therefore
Cox regression analysis is restricted to a limited number of
potential confounders.
Conclusion
Our findings demonstrate that CV disease in terms of LVH
and reduced LVEF in addition to residual urine production
and Kt/V determine NT-proBNP levels. Post-HD concentra-
tions of NT-proBNP were lower than pre-HD levels; both
values were predictive of mortality. Levels could be
interpreted as an individual risk marker, which makes NT-
proBNP monitoring an intriguing perspective.
MATERIALS AND METHODS
Patients
The study was designed as a single center study with prevalent
patients recruited from the hemodialysis department, State Uni-
versity Hospital of Copenhagen. One hundred and nine patients
were included. All patients underwent physical examination,
electrocardiogram, and echocardiography assessing left ventricular
ejection fraction (LVEF) and left ventricular mass index (LVMI),
measurement of 24-h ambulatory BP and ankle-brachial index. All
patients received regular bicarbonate HD using high-flux filters 3–4
times a week in sessions lasting 3–4.5 h. Kt/V (K¼ dialyzer clearance,
t¼ time, V¼ volume of water a patient’s body contains) is a
surrogate marker for the elimination of low molecular weight toxins
and represents a standard for effectiveness of HD with a desired
value of 3.6 per week. Volume overload is defined as the increase in
bodyweight measured just before HD in relation to clinically
estimated dry weight.
Ischemic heart disease was defined as present in patients with
previous acute myocardial infarction, coronary artery bypass
grafting, or percutaneous coronary intervention or in patients with
symptoms suggesting stable angina pectoris and responding to anti-
ischemic treatment. Systolic CHF was defined in accordance with
the guidelines from the European Society of Cardiology as
symptoms (shortness of breath or ankle swelling) and objective
evidence suggesting cardiac dysfunction, in this study also including
patients with estimated LVEF p40%.36 The duration of chronic
renal failure is estimated as time since the first discovery of reduced
renal function. During follow-up, all hospitalizations and causes of
death were registered by continuous observation of medical records.
Primary end points were acute coronary syndromes, ischemic
stroke, sudden death, CV death, and total mortality.
According to the Declaration of Helsinki Principles, the local
ethical committee approved the protocol, and written informed
consent was obtained from each participant.
Measurement of clinical parameters
Echocardiography (HP/Agilent Sonos 4500) was performed on a
non-dialysis day. Left ventricular dimensions and LVEF were
measured by standard techniques; LVEF was estimated by nine-
segment wall motion score index. Motion score index multiplied by
0.3 gives an estimate of LVEF.37 Left ventricular mass (LVM) was
calculated according to the regression equation described by
Devereux:
LVM¼ 0.832(IVSDþ LVEDDþPWTD)3–(LVEDD)3þ 0.6 and in-
dexed to height2.7 to determine LVMI, presented in g/m2.7. Left
ventricular hypertrophy (LVH) was defined as LVMI450 g/m2.7 in
male subjects and 447 g/m2.7 in female subjects.
Standard measurements of 24-h ambulatory BP were performed
by oscillometry (A&D TM2420/TM2421, Spacelab 90217). In
patients who refused to undergo ambulatory BP monitoring
hypertension was estimated by comparison of BP before and after
HD for a period of 1 month before study inclusion. HD BP was
determined by standard techniques just before the HD session with
an autoinflation BP monitor (A&D UA-779) and examination BP
was determined by a non-invasive volume-oscillometric method
(Artcomp, Critikon, GE Healthcare, Tampa, FL, USA) after 15 min
of rest, in both using cuffs adapted to arm circumference.
Hypertension was defined as systolic BP4135 mm Hg and/or
diastolic BP485 mm Hg independent of method of measurement.38
Laboratory measurements
Blood samples were drawn from the arteriovenous fistula just before
and at the end of HD before discontinuation of the extra corporal
circulation. Samples were centrifuged and serum was stored at
701C before thawed and analyzed within 1 year of sampling.
Serum NT-proBNP was measured using Elecsys 2010 (Roche
Diagnostics, Mannheim, Germany). Cutoff used was 125 pg/ml
taken from the manufacturer’s package insert. The lower detection
limit is 5 pg/ml and the coefficient of variation (20%) iso50 pg/ml.
A small substudy on 10 randomly assigned patients was
performed in order to evaluate the change in concentration over
the cartridge. Pre- and post-cartridge blood samples were collected
30 min after initiation of HD with immediate determination of
concentrations of NT-proBNP. No further clinical data were
obtained on these patients.
Statistical analysis
All data with a normal distribution are presented as mean7s.d.,
otherwise as median with range or quartiles in parenthesis. NT-
proBNP values were skewed and consequently data underwent
normalization by natural logarithmic transformation (ln) if required
for statistical analysis. Differences between groups were examined
with Student’s t-tests or Mann–Whitney. Categorical data were
compared using w2 analysis. Relationships between two variables
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were determined by linear regression analysis, and multiple
regression analysis was used to assess the combined influence of
variables on serum NT-proBNP concentrations. The risk of death
among patients with increasing concentrations of serum NT-
proBNP was compared using the Kaplan–Meier method. The cutoff
values were based on quartiles, and differences between the groups
were analyzed with the log-rank test. The independent power of
different variables to predict overall mortality was assessed using
Cox proportional hazards regression analysis. A value of Po0.05
was considered statistically significant. All statistical analyses were
performed using the SPSS 11.5 PC software.
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